Summary
36 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $292.6M in the last fiscal year, 4.3% of its market value.
- It could repay all its net debt from 2.2 years of operating profit.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 13% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Analysts expect revenue to fall by 32% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue fell by 1.2% a year over 5 years. Over the last 3 years it fell by 13% a year. For the next fiscal year analysts expect revenue to fall by 32%.
Growth in detailDoes it make money?
ReasonablyWhere 100 AUD of revenue goes
- Cost of sales 72 AUD
- Sales and administration 13 AUD
- Taxes and other 10 AUD
- Net profit 4.5 AUD
Net profit, industry median (Chemicals - Specialty) 5.9 AUD
Out of every 100 AUD of revenue, 4.5 AUD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.21%
You receive $0.03 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $4 is 47% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.